Shandong Yingsheng Biotechnology Co., Ltd. (hereinafter referred to as Yingsheng), established in 2009, is a pioneer in technology development, quality control and technical services in the field of clinical mass spectrometry in China, and also a high-tech enterprise integrating R&D, production, sales and third-party medical testing services. Yingsheng built a leading domestic gene detection platform and mass spectrometry detection platform around metabonomics and genomics, covering the fields of birth defect screening, disease prevention and human health services, and won more than 20 national patents and 6 software copyrights. Participating in the construction of 1 industry standard and 12 enterprise standards, passing the ISO13485 quality management system and GB/T29490-2013 intellectual property management system certification, it is the "Thirteenth Five-Year Plan" of Shandong Province. Since its establishment, Yingsheng has focused on the field of clinical mass spectrometry for more than ten years. After careful polishing and precipitation, it has trained a large number of R&D and technical talents in the field of mass spectrometry. At the same time, it is in line with the development of international industries and combines the advantages of independent innovation projects and talent structure to carry out strategic cooperation with internationally renowned companies, such as Thermo Fisher of the United States, Hamilton of Switzerland and Biotage of Sweden. Yingsheng-Thermo Fisher Scientific Mass Spectrometry Localization Production Center, Yingsheng-Thermo Fisher Scientific International R&D and Transformation Center, Yingsheng-Mass Spectrometry Pretreatment Artificial Intelligence R&D Center, Yingsheng-China Clinical Mass Spectrometry Maintenance Center, and Yingsheng -IBP Bio-Mass Spectrometry Transformation Research Institute have been successfully established, and they are committed to the platform technology development and achievement transformation of mass spectrometry, molecule and pathology. Yingsheng's product lines include: high performance liquid chromatography-tandem mass spectrometry detection system, inductively coupled plasma mass spectrometer, mass spectrometry automatic intelligent processing platform, screening reagents for 48 genetic metabolic diseases of newborns, reagents for determination of 14 full spectrum vitamins, blood drug concentration monitoring reagents, deafness gene detection reagents, novel coronavirus 2019-nC0V nucleic acid detection kit, etc.
Full spectrum vitamin test
Total number of deafness genetic tests completed
Neonatal genetic and metabolic disease screening